| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,867 | 0,879 | 20:34 | |
| 0,867 | 0,879 | 20:31 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:29 | Circio Holding ASA: Circio announces research collaboration with the Universidad de Santiago de Compostela s TraffikGene project to advance non-viral circVec delivery | 1 | Oslo Børs | ||
| Mo | Circio Holding ASA: Circio announces publication of two abstracts selected for presentation at the ASGCT annual meeting | - | Oslo Børs | ||
| Fr | Circio Holding ASA: Circio announces that the ongoing feasibility study with a major global pharmaceutical corporation is progressing to in vivo testing | 2 | Oslo Børs | ||
| Fr | Circio Holding ASA: Cancellation of Subsequent Offering | 1 | Oslo Børs | ||
| 17.04. | Circio Holding ASA Notice of annual general meeting 2026 | 1 | Oslo Børs | ||
| 16.04. | Circio Holding ASA: Annual Report and Remuneration Report for 2025 | 2 | Oslo Børs | ||
| CIRCIO Aktie jetzt für 0€ handeln | |||||
| 16.04. | Circio Holding ASA: Mandatory adjustment of RSUs and share options following recently completed rights issue | 2 | Oslo Børs | ||
| 15.04. | Circio, Acuitas Partner to Advance In Vivo CAR-T Therapy Using Circular RNA | 1 | Contract Pharma | ||
| 15.04. | Circio Holding ASA: Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics | 20 | Oslo Børs | ||
| 14.04. | Circio Holding ASA: Registration of share capital increase following private placement of approximately NOK 250 million | 3 | Oslo Børs | ||
| 10.04. | Circio Completes Oversubscribed Financing, With Proceeds to Accelerate Circular RNA Platform | 3 | Contract Pharma | ||
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2026 | 224 | Xetra Newsboard | Das Instrument TA50 NO0013033795 CIRCIO HOLDING NK 0,60 EQUITY wird ex Kapitalmassnahme gehandelt am 09.04.2026 The instrument TA50 NO0013033795 CIRCIO HOLDING NK 0,60 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 08.04. | Circio Holding ASA: Ex. right to participate in potential subsequent offering today | 4 | Oslo Børs | ||
| 26.03. | Circio Holding ASA: Circio enters in vivo cell therapy collaboration with United Immunity | 18 | Oslo Børs | ||
| 18.03. | Circio Holding ASA: Circio selected for oral presentation at prestigious ASGCT annual meeting | 2 | Oslo Børs | ||
| 26.02. | Circio Holding ASA: Correction - Mandatory notification of trade by primary insider related to the rights issue | 12 | Oslo Børs | ||
| 19.02. | Circio Holding ASA: Circio invites to R&D and corporate update webcast on 26 February 2026 | 1 | Oslo Børs | ||
| 17.02. | Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million | - | Oslo Børs | ||
| 16.02. | CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING | 1 | Oslo Børs | ||
| 14.02. | Circio Holding ASA: Circio announces allocation of stock options to key employees | - | Oslo Børs |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,65 | -1,72 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie mit +46% - kommt das Comeback? | Die Evotec-Aktie hat zuletzt kräftig zugelegt und stieg um rund +46% an. Damit hat sich das Chartbild deutlich verbessert und eine mögliche Trendwende rückt in den Fokus. Nach der dynamischen Rallye... ► Artikel lesen | |
| MEDIGENE | 0,027 | -2,90 % | Medigene: Zurückziehung - 18.11.2025 | ||
| PAION | 0,047 | -26,19 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,372 | -1,70 % | SCHOCKMELDUNG bei Valneva: 3,7% Verlust und das könnte erst der Anfang sein - Handeln Sie, bevor es zu spät ist | ||
| NOVAVAX | 6,650 | -1,77 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| OCUGEN | 1,426 | -0,28 % | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead | ||
| INOVIO PHARMACEUTICALS | 0,988 | +0,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,800 | -3,07 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| INFLARX | 1,451 | +1,40 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| BAVARIAN NORDIC | 24,520 | -1,29 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| EDITAS MEDICINE | 2,390 | -8,78 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| SAREPTA THERAPEUTICS | 17,760 | -1,33 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| CARDIOL THERAPEUTICS | 1,102 | -6,29 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program | Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart adds James Breitmeyer to board of directors |